Drug Trial Radar · NCT03582618
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Jul 12, 2018
Primary completion
Nov 16, 2021
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- TaiRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.
Conditions
- Hepatocellular Carcinoma
- Advanced Cancer
Interventions
SorafenibDrug
Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
CVM-1118Drug
CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 24 weeks after the last subject starts CVM-1118
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Charleston Hematology Oncology Associates
Charleston, South Carolina
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.